ClinicalTrials.gg
RecruitingNCT05916963FIREStonesUpdated Nov 9, 2026

Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser

A Phase 3 interventional study of Furosemide 40 mg in Kidney Stone, sponsored by University Hospital, Tours. Recruiting at 9 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University Hospital, Tours · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Nov 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
374
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Kidney Calculi with a site in France — 5 open to participants now, 5 under way, 2 of them phase 3. Kidney Calculi · France.

Planned enrollment
3rd of 11
374 · median 140
Started
2024
the only one that year
Phase 3
5 of 11
2 open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
University Hospital, Tours

Among the 11 studies in Kidney Calculi with a site in France, this one is the 3rd largest by planned enrollment, is the only one that started in 2024, is one of 5 in phase 3, and was the 9th registered.

Kidney Calculi

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

Browse Kidney Calculi studies →

Open to participants now

5 of the 11 studies in Kidney Calculi with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Kidney Calculi with a site in France, or all of them as a file.
02

Study summary

In view of the positive results of the numerous studies conducted on forced diuresis after extra-corporeal lithotripsy, the investigators chose to evaluate forced diuresis by injection of Furosemide associated with intravenous hydration, which has never before been the subject of a specific analysis.

Read the detailed description

Flexible ureteroscopy is the most common technique to treat kidney stones and is the treatment of choice in France.

Kidney stones destruction requires its laser pulverization into small fragments in order to remove them through the ureter or improve their spontaneous expulsion along the urinary tract. However, most of the time, all the micro-fragments and dust created during stone destruction cannot be extracted using our surgical tools, and may stay intra-renally at the end of the procedure. Although these micro-fragments are expected to disappear spontaneously by the natural flushing and peristalsis of the upper urinary tract, they remain at risk of stagnation that could be the nest of new aggregation and stone formation.

Adjuvant treatments (such as forced diuresis, inversion or mechanical pressure) were previously described to improve the expulsion of stone fragments after extra-corporeal shock wave lithotripsy.

Nevertheless, the impact of adjuvant treatment after flexible ureteroscopy remains unclear and mainly theoretical.

In view of the positive results of the numerous studies conducted on forced diuresis after extra-corporeal lithotripsy, the investigators chose to evaluate forced diuresis by injection of Furosemide associated with intravenous hydration, which has never before been the subject of a specific analysis.

Loop diuretics (including Furosemide) significantly increase diuresis, which results in a greater flow of urine into the renal cavities, improving the chances of evacuating the residual fragments of the stone destroyed during flexible ureteroscopy, before they can sediment in the fundus of the renal calices or in the pyelon. Therefore, the investigators hypothesize that a forced diuresis with an injection of Furosemide at the end of ureteroscopy could improve the micro-fragments and stones dust clearance.

03

Conditions studied

  • Kidney Stone

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 years old and \< 80 years old
  • With the need to perform a flexible ureteroscopy with destruction of the kidney stones with laser
  • Participants covered by or entitled to social security
  • Written obtained from the participant
  • Ability for participant to comply with the requirements of the study

Exclusion criteria

Exclusion Criteria:

  • Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, minors, and persons subject to a legal protection measure: guardianship or trusteeship)
  • to Furosemide:

    • Hyper-sensitivity to the active substance or one of the
    • Hyper-sensitivity to Sulfonamide
    • Renal failure with oligo-anuria to Furosemide
    • Hypokalemia \< 3,5 mmol/L
    • Severe hyponatremia
    • Hypovolemia with or without hypotension or dehydration
    • Ongoing hepatitis, hepatic insufficiency severe and hepatic encephalopathy
  • Patient having Furosemide as usual treatment
  • Patient requiring an injection of Aminoside or Vancomycin before or during the procedure
  • Participation in other interventional research with an drug or medical device
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
374 participants (estimated)

Study arms

  • Experimental
    Furosemide

    Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.

    Drug: Furosemide 40 mg

  • No intervention
    Usual care

    Usual care, without injection of Furosemide.

Interventions

  • DrugFurosemideStudies of FurosemideFurosemide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.

06

What researchers measure

Primary outcomes

  1. Rate of stone free patients

    Rate of stone-free patients 3 months after a flexible ureteroscopy for renal stone laser destruction, evaluated on the low dose abdomino-pelvic CT-Scan. A centralized review of the images will be performed by two specialized radiologists, in a blind and crossed way to allow a homogenization of the results

    Time frame: At 3 months

Secondary outcomes

  1. Rate of urinary infection

    Rate of post-operative urinary tract infection will be assessed within 30 days after surgery on the combination of: * Fever higher than 38.5°C and/or, * Chills and/or, * Clinical symptoms (supra-pubic pain, dysuria, pollakiuria, urgency, urinary burning, back pain radiating to the genitals, hematuria) and/or * Positive urine culture with a significant bacteriuria threshold defined as bacteriuria ≥10\^5 UFC/mL with one or two bacterial species.

    Time frame: From baseline to 30 days

  2. Pain in a scale

    Post-operative pain will be assessed on numerical pain scale in the recovery room, in the service and at the discharge. Pain scale is from 0 (no pain) to 10 (as bad as it could be nothing else matters)

    Time frame: During the hospital stay

  3. Opioid consumption

    The use of opioids will be reported

    Time frame: During the hospital stay, an average of 1 day

  4. Number of participants with adverse events

    Number of participants with Furosemide adverse events

    Time frame: From baseline to 3 months, an average of 1 day

07

Study locations

9 of 9 sites recruiting
08

References and documents

Publications

  • Letouche ML, Giraudeau B, Agier MS, Bruyere F. FIRE Stones: impact of forced diuresis on the residual fragment rate after flexible ureteroscopy for destruction of kidney stones with laser-protocol for a randomized controlled two-parallel group multicenter trial with blinding evaluation. Trials. 2024 Jul 4;25(1):455. doi: 10.1186/s13063-024-08309-0. PubMed 38965611 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2024 (actual). Primary completion is estimated for Apr 2028, 51 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Apr 2026 → Apr 2028 and completion Apr 2026 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2023
First posted
Jun 23, 2023
StartActual
Jan 4, 2024
Primary completionEst.
Apr 2028was Apr 2026
CompletionEst.
Apr 2028was Apr 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 3, 2026→Apr 2028
Nov 9, 2026
Study completion
Apr 3, 2026→Apr 2028
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Apr 3, 2026→Apr 2028
    Study completion Apr 3, 2026→Apr 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05916963
Responsible party
Sponsor
First posted
Jun 23, 2023
Start date
Jan 4, 2024
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Marie-Lou LETOUCHE, MD
Contact
marielou.letouche@gmail.com
+33247474665

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Furosemide

Start the discussion